Which Pharma Stocks Lead the 2020s? Here's the Best Performer Yet

The past few years have been transformative for the pharmaceutical industry. While debates continue about whether this decade will earn its own nickname as another “Roaring 20s,” one thing is certain: the best pharma stocks have delivered exceptional returns for savvy investors. The overall equity market has climbed over 30% from the start of 2020, but within the healthcare sector, a select group of pharmaceutical companies has vastly outpaced this benchmark, driven by breakthrough products, strategic positioning, and timely innovation.

A Decade of Pharmaceutical Stock Winners

The pharmaceutical landscape has been remarkably varied in its returns. Only a handful of major pharma stocks have managed to surpass the S&P 500’s solid performance since 2020, and notably, many established players in the sector have actually declined. Among the traditional big pharma companies—those with substantial market capitalizations and diversified portfolios—just six have beaten the broader market. This narrow group represents the true standout performers of the decade so far.

The distinction between “pharma” and “biotech” becomes blurry when examining best pharma stocks, as some top performers blur this traditional categorization. What’s clear, however, is that success in this decade has gone to companies that could capitalize on specific tailwinds: whether that meant pandemic-driven opportunities or demographic shifts toward metabolic disease treatments.

The Top Three Pharmaceutical Contenders

Three pharmaceutical companies have emerged as the most impressive performers, each for distinct reasons. Understanding their rise illuminates what drives pharmaceutical stock outperformance in the 2020s.

Regeneron Pharmaceuticals has seen its share price more than double over the period. The company’s ascent was turbocharged by the explosive demand for its monoclonal antibody therapies during the early COVID-19 pandemic, when treatments were scarce and desperate. This early-mover advantage in therapeutic antibodies positioned Regeneron as a major player when investors were hungry for healthcare solutions.

Novo Nordisk claims the number two position among major pharma stocks, with gains exceeding 200%. The Danish pharmaceutical giant’s surge stems largely from one transformative drug: semaglutide. Marketed as Ozempic for type 2 diabetes management and Wegovy for weight loss treatment, this single product has generated enormous commercial momentum. The off-label prescription trend for weight loss has further amplified its market potential and profitability.

Yet neither of these strong performers quite reaches the summit of pharmaceutical stock performance in the 2020s.

Why Eli Lilly Emerges as the Best Pharma Stock

Eli Lilly and Company stands as the unequivocal leader among all major pharmaceutical stocks this decade. The Indiana-based giant’s shares have advanced nearly 300% over roughly four years—a staggering achievement that now places it as the highest market capitalization pharmaceutical company globally, and the largest healthcare company by market valuation.

What makes Eli Lilly’s performance particularly remarkable is that it combines the winning elements from both rival pharma competitors. Like Regeneron, Lilly capitalized on COVID-19 antibody treatments. Yet similar to Novo Nordisk’s model, the company has built a massive revenue engine around metabolic disease therapies.

Eli Lilly’s diabetes franchise represents a formidable competitive moat. The blockbuster drugs Trulicity and Jardiance have become household names among endocrinologists, while Humalog insulin injections maintain steady demand. But the rising star of this portfolio is Mounjaro, a newer treatment for type 2 diabetes that has rapidly gained market share. Following Novo Nordisk’s playbook, Lilly is pursuing regulatory approval for Mounjaro as a weight loss medication—a market opportunity that analysts estimate could generate peak annual sales exceeding $50 billion.

Beyond metabolic disease, Eli Lilly maintains substantial oncology capabilities. Cancer therapeutics including Verzenio, Cyramza, Retevmo, and Tyvyt contribute meaningful revenue streams and portfolio diversification. The company also brings relevant products in autoimmune disease treatment (Taltz and Olumiant) and neurology (Emgality for migraine management).

The most intriguing upcoming catalyst involves donanemab, a treatment for early-stage Alzheimer’s disease. Recent clinical data demonstrated the drug’s ability to meaningfully slow cognitive decline in affected patients. If regulatory approval arrives as expected, donanemab could become another blockbuster—addressing a massive unmet medical need in aging populations.

Evaluating Valuation and Growth Prospects

Investors naturally question whether Eli Lilly’s extraordinary run can continue when examining the stock’s valuation metrics. The company trades at a forward price-to-earnings multiple exceeding 41x current expectations—substantially above the sector median of approximately 16x for S&P 500 pharmaceutical companies. This premium valuation raises legitimate questions about whether the best pharma stock valuations remain reasonable.

However, valuation multiples alone don’t capture the complete investment picture. Lilly’s growth trajectory remains compelling. Mounjaro’s commercialization is still in its early innings, with market penetration rates suggesting decades of growth potential ahead. Donanemab represents a potential multi-billion-dollar revenue stream from an Alzheimer’s market that has historically seen limited effective treatment options. The company’s existing portfolio—which generated consistent revenue well before these recent successes—provides a stable foundation supporting further expansion.

For long-term investors seeking exposure to the best pharma stocks, Eli Lilly represents an intriguing choice despite its lofty valuation. The company’s diverse product pipeline, blockbuster commercial achievements, and emerging therapeutic opportunities suggest that while the 300% gains of the past four years may not repeat perfectly, meaningful returns remain plausible for patient shareholders. The question is no longer which pharmaceutical company has performed best—but whether that performance can sustain through the remainder of this decade.